INVA
Innoviva, Inc.
Key Financials
Net Income
$4.4M
N/A
Operating Income
$163.7M
↓ 1.9%
Gross Profit
$307.7M
↑ 3.9%
EPS (Diluted)
$3.30
↑ 816.7%
Revenue
$411.3M
↑ 14.7%
Total Assets
$1.6B
↑ 25.7%
Long-term Debt
$257.7M
↑ 0.6%
Operating Cash Flow
$196.9M
↑ 4.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/18/2026 | View on SEC |
| SCHEDULE 13D/A | 5/13/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INVA |
| Company Name | Innoviva, Inc. |
| CIK | 1080014 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6502389600 |